← back to search

Myla Goldman

Children's Hospital of Richmond at VCU · US
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Balance, Gait, and Falls Prevention, Amyotrophic Lateral Sclerosis Research, and Effects of Vibration on Health.
h-index
38
citations
6,102
works
151
NIH funding
primary concept
email

Recent publications

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial
The Lancet Neurology 2023cited by 132position: middledoi
Multiple sclerosis progression: time for a new mechanism-driven framework
The Lancet Neurology 2022cited by 587position: middledoi
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Neurology 2020cited by 104position: middledoi
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis
JAMA Neurology 2020cited by 43position: middledoi
Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data
Neurology 2019cited by 93position: firstdoi
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
New England Journal of Medicine 2018cited by 280position: middledoi
The state of clinical research in neurology
Neurology 2018cited by 18position: lastdoi
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
Multiple Sclerosis Journal 2017cited by 64position: middledoi
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
Contemporary Clinical Trials 2016cited by 66position: middledoi
Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project
Journal of the American College of Radiology 2016cited by 58position: middledoi
Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale
Multiple Sclerosis Journal 2016cited by 44position: firstdoi
Evidence for the different physiological significance of the 6- and 2-minute walk tests in multiple sclerosis
BMC Neurology 2012cited by 61position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John H. Pula · University of Illinois Chicago2 papers (2012–2016)Robert W. Motl · University of Illinois Urbana-Champaign2 papers (2012–2016)Jeffrey A. Cohen · Cleveland Clinic2 papers (2016–2019)John R. Rinker · University of Alabama at Birmingham1 papers (2016–2016)Paul M. Matthews · Imperial College London1 papers (2019–2019)Bianca Weinstock‐Guttman · ECD for the Masses (United States)1 papers (2020–2020)Amit Bar‐Or · University of California System1 papers (2020–2020)Benzi M. Kluger · University of Rochester Medical Center1 papers (2018–2018) · 1 papers (2020–2020)Diego Cadavid · ID Genomics (United States)1 papers (2016–2016)Susanne Mientus · Novartis (Switzerland)1 papers (2020–2020)Swathi Balantrapu · University of Illinois Urbana-Champaign1 papers (2012–2012)Ying Zhang · Xihua University1 papers (2020–2020)Deborah A. Hall · Rush University1 papers (2018–2018)David Jones · University of Virginia1 papers (2016–2016) · 1 papers (2016–2016)Corey C. Ford · Medical College of Wisconsin1 papers (2020–2020)Rajesh Karan · Novartis (Switzerland)1 papers (2020–2020)Nicholas G. LaRocca · National Multiple Sclerosis Society1 papers (2019–2019)Elliot Dickerson · University of California, San Francisco1 papers (2016–2016)